Enison (BioDeep_00000395643)

 

Secondary id: BioDeep_00000859019

PANOMIX_OTCML-2023


代谢物信息卡片


3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate (1:1) (salt)

化学式: C43H57N5O11S (851.3775)
中文名称: 硫酸长春地辛
谱图信息: 最多检出来源 Chinese Herbal Medicine(otcml) 78.16%

分子结构信息

SMILES: CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O.OS(=O)(=O)O
InChI: /m1./s1

描述信息

Vindesine sulfate is an alkaloid sulfate salt. It has a role as an antineoplastic agent. It is functionally related to a vindesine.
Vindesine Sulfate is the sulfate salt form of Vindesine. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI)
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators
D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents
D000970 - Antineoplastic Agents > D014748 - Vinca Alkaloids
Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 μM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo[1].

同义名列表

24 个代谢物同义名

3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate (1:1) (salt); 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate; Desacetylvinblastine amide sulfate; N-a-Boc-D-2,4-Diaminobutyricacid; VDSDesacetyl Vinblastine amide; Vindesine sulfate salt hydrate; Vindesine sulfate (JAN/USAN); Desacetyl Vinblastine amide; Desacetylvinblastine Amide; Vindesine sulfate- Bio-X; Vindesine sulfate salt; VINDESINE SULFATE(RG); VindesineSulfateSalt; Vindesine (sulfate); Sulfate, Vindesine; Vindesine sulfate; Fildesin (TN); Tox21_113632; Vindesine; Vindesin; Eldisine; Eldesine; FILDESI; Enison



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Simin Luo, Xuan Zhang, Xiang Xiao, Wenting Luo, Zixuan Yang, Songqi Tang, Wei Huang. Exploring Potential Biomarkers and Molecular Mechanisms of Ischemic Cardiomyopathy and COVID-19 Comorbidity Based on Bioinformatics and Systems Biology. International journal of molecular sciences. 2023 Mar; 24(7):. doi: 10.3390/ijms24076511. [PMID: 37047484]
  • S Bernard, L Hachon, J F Diasonama, C Madaoui, L Aguinaga, E Miekoutima, H Moatti, Emeline Perrial, I Madelaine, P Brice, Catherine Thieblemont. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma. Annals of hematology. 2021 Apr; 100(4):979-986. doi: 10.1007/s00277-020-04341-7. [PMID: 33608849]
  • Chenrong Huang, Fan Xia, Ling Xue, Linsheng Liu, Yicong Bian, Zhengming Jin, Liyan Miao. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3. Cancer chemotherapy and pharmacology. 2020 02; 85(2):433-441. doi: 10.1007/s00280-019-03972-6. [PMID: 31691080]
  • Jin-Hu Wang, Min-Ju Li, Da-Xing Tang, Shan Xu, Jun-Qing Mao, Jia-Bin Cai, Min He, Qiang Shu, Can Lai. Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for treatment of clear cell sarcoma of the kidney in children. Journal of pediatric surgery. 2019 Mar; 54(3):550-556. doi: 10.1016/j.jpedsurg.2018.09.012. [PMID: 30318310]
  • Xueping Lei, Minfeng Chen, Maohua Huang, Xiaobo Li, Changzheng Shi, Dong Zhang, Liangping Luo, Youwei Zhang, Nan Ma, Heru Chen, Huafeng Liang, Wencai Ye, Dongmei Zhang. Desacetylvinblastine Monohydrazide Disrupts Tumor Vessels by Promoting VE-cadherin Internalization. Theranostics. 2018; 8(2):384-398. doi: 10.7150/thno.22222. [PMID: 29290815]
  • Kui Liu, Yue-Lu Guo, Zi-Long Yao, Xiang-Shu Jin, Ran Zhang, Xiao-Pin Han, Xiao-Ning Gao, Li Yu, Yu Jing. [Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL]. Zhongguo shi yan xue ye xue za zhi. 2015 Dec; 23(6):1560-3. doi: 10.7534/j.issn.1009-2137.2015.06.006. [PMID: 26708871]
  • Rong-Hua Zhu, Huan-De Li, Hua-Lin Cai, Zhi-Ping Jiang, Ping Xu, Li-Bo Dai, Wen-Xing Peng. Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2014 Aug; 96(?):31-6. doi: 10.1016/j.jpba.2014.03.017. [PMID: 24721203]
  • A Jarfaut, R Santucci, D Levêque, R Herbrecht. Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin. Medecine et maladies infectieuses. 2013 Jan; 43(1):39-41. doi: 10.1016/j.medmal.2012.11.006. [PMID: 23332768]
  • Yukitaka Nakano, Tetsuya Saita, Hiroshi Fujito. [Development of a specific and sensitive enzyme-linked immunosorbent assay for vindesine]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2012; 132(6):727-32. doi: 10.1248/yakushi.132.727. [PMID: 22687732]
  • Haoyuan Zhang, Rending Wang, Huiping Wang, Ying Xu, Jianghua Chen. Membranoproliferative glomerulonephritis in Castleman's disease: a systematic review of the literature and 2 case reports. Internal medicine (Tokyo, Japan). 2012; 51(12):1537-42. doi: 10.2169/internalmedicine.51.6298. [PMID: 22728487]
  • Min-Ju Li, Yin-Bao Zhou, Yong Huang, Da-Xing Tang, Shan Xu, De-Hua Wu, Yi-Ying Zhang, Hong-Feng Tang. A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy. Journal of vascular and interventional radiology : JVIR. 2011 Mar; 22(3):279-86. doi: 10.1016/j.jvir.2010.11.025. [PMID: 21353980]
  • Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yasumasa Nishimura, Kayoko Tsujino, Miyako Satouchi, Shinzoh Kudo, Toyoaki Hida, Masaaki Kawahara, Koji Takeda, Nobuyuki Katakami, Toshiyuki Sawa, Soichiro Yokota, Takashi Seto, Fumio Imamura, Hideo Saka, Yasuo Iwamoto, Hiroshi Semba, Yasutaka Chiba, Hisao Uejima, Masahiro Fukuoka. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Aug; 28(23):3739-45. doi: 10.1200/jco.2009.24.5050. [PMID: 20625120]
  • Afshin Azhir, Nahid Reisi, Diana Taheri, Atoosa Adibi. Post transplant anaplastic large T-cell lymphoma. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2009 Jul; 20(4):646-51. doi: NULL. [PMID: 19587509]
  • Friederike Egberts, Wolfgang N Hitschler, Michael Weichenthal, Axel Hauschild. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma research. 2009 Feb; 19(1):31-5. doi: 10.1097/cmr.0b013e32831993cc. [PMID: 19104452]
  • Tatsuya Nakamura, Nobukazu Fuwa, Takeshi Kodaira, Hiroyuki Tachibana, Takuya Tomoda, Rie Nakahara, Haruo Inokuchi. Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy. Lung. 2008 Mar; 186(2):91-6. doi: 10.1007/s00408-007-9063-5. [PMID: 18097718]
  • Tobias Paffhausen, Manfred Schwab, Frank Westermann. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer letters. 2007 May; 250(1):17-24. doi: 10.1016/j.canlet.2006.09.010. [PMID: 17141950]
  • Sasha Bernatsky, Rosalind Ramsey-Goldman, Silvy Lachance, Christian A Pineau, Ann E Clarke. Lymphoma in a patient with systemic lupus erythematosus. Nature clinical practice. Rheumatology. 2006 Oct; 2(10):570-4; quiz 575. doi: 10.1038/ncprheum0295. [PMID: 17016483]
  • Cécile Fohrer, Sophie Caillard, Argyro Koumarianou, Bernard Ellero, Marie-Lorraine Woehl-Jaeglé, Carole Meyer, Eric Epailly, Marie-Pierre Chenard, Bruno Lioure, Shanti Natarajan-Ame, Frédéric Maloisel, Philippe Lutun, Romain Kessler, Bruno Moulin, Jean-Pierre Bergerat, Philippe Wolf, Raoul Herbrecht. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. British journal of haematology. 2006 Sep; 134(6):602-12. doi: 10.1111/j.1365-2141.2006.06228.x. [PMID: 16889621]
  • Hiroshi Handa, Hiroyuki Irisawa, Satoru Komatsumoto, Takafumi Matsushima, Norifumi Tsukamoto, Yoshihisa Nojima, Hirokazu Murakami. [Plasmacytoma with multiple hypervascular lesions revealed by angiography in a patient with multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2006 Jun; 47(6):521-5. doi: NULL. [PMID: 16862980]
  • Sabine Brennecke, Martin Deichmann, Helmut Naeher, Hjalmar Kurzen. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma research. 2005 Dec; 15(6):515-22. doi: 10.1097/00008390-200512000-00006. [PMID: 16314737]
  • Mario Ojeda-Uribe, Annick Brunot, Monique Issler. [Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case]. Revista medica de Chile. 2005 Nov; 133(11):1349-54. doi: 10.4067/s0034-98872005001100011. [PMID: 16446859]
  • Marianne Ryberg, Dorte Nielsen, Kell Osterlind, Per Kragh Andersen, Torben Skovsgaard, Per Dombernowsky. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast cancer research and treatment. 2005 Jun; 91(3):217-25. doi: 10.1007/s10549-005-0323-x. [PMID: 15952055]
  • F Prignano, M Coronnello, N Pimpinelli, P Cappugi, E Mini, B Giannotti. Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. Cancer letters. 2002 Dec; 186(2):183-92. doi: 10.1016/s0304-3835(02)00343-9. [PMID: 12213288]
  • Sachio Fushida, Furui Nao, Shinichi Kinami, Itasu Ninomiya, Takashi Fujimura, Genichi Nishimura, Tetsuo Ohta, Koichi Yokogawa, Kenichi Miyamoto, Koichi Miwa. [Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination]. Gan to kagaku ryoho. Cancer & chemotherapy. 2002 Oct; 29(10):1759-63. doi: NULL. [PMID: 12402426]
  • R Moog, A M Burger, M Brandl, J Schüler, R Schubert, C Unger, H H Fiebig, U Massing. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer chemotherapy and pharmacology. 2002 May; 49(5):356-66. doi: 10.1007/s00280-002-0428-4. [PMID: 11976829]
  • Jacek Zych, Monika Szturmowicz, Anna Sakowicz, Janina Słodkowska, Monika Załeska, Elzbieta Radzikowska, Jolanta Załeska, Zbigniew Jodkiewicz, Ewa Rowińska-Zakrzewska. [Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer]. Pneumonologia i alergologia polska. 2002; 70(5-6):278-83. doi: NULL. [PMID: 12518626]
  • H Kunikane, K Watanabe, M Fukuoka, N Saijo, K Furuse, H Ikegami, Y Ariyoshi, S Kishimoto. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. International journal of clinical oncology. 2001 Dec; 6(6):296-301. doi: 10.1007/s10147-001-8031-y. [PMID: 11828949]
  • C M Jiang, M R Pang, L Y Gong. [Clinical observation on effect of chemotherapy combined with Chinese medicine in treating advanced tumor patients and on immunologic parameters]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2001 Dec; 21(12):885-7. doi: ". [PMID: 12575585]
  • S Tsuchiya, Y Ohe, T Sugiura, N Fuwa, Y Kitamoto, K Mori, H Kobayashi, K Nakata, T Sawa, K Hirai, T Etoh, H Saka, A Saito, H Fukuda, N Ishizuka, N Saijo. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601). Japanese journal of clinical oncology. 2001 Oct; 31(10):488-94. doi: 10.1093/jjco/hye106. [PMID: 11696618]
  • B Hero, D H Hunneman, M Gahr, F Berthold. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Medical and pediatric oncology. 2001 Jan; 36(1):220-3. doi: 10.1002/1096-911x(20010101)36:1<220::aid-mpo1053>3.0.co;2-6. [PMID: 11464889]
  • M Colombi, A Guffanti, A Alietti, M L Latargia, C Vener, A T Maiolo, L Baldini. OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma. Leukemia & lymphoma. 2000 Dec; 40(1-2):87-94. doi: 10.3109/10428190009054884. [PMID: 11426632]
  • P G Gobbi, C Broglia, R Bertè, M P Petrilli, S Molica, F Angrilli, E Iannitto, M L Ghirardelli, N Di Renzo, L Cavanna, E Ascari. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease. Haematologica. 2000 Jul; 85(7):722-8. doi: NULL. [PMID: 10897124]
  • M J Zelefsky, W K Kelly, H I Scher, H Lee, T Smart, E Metz, L Schwartz, Z Fuks, S A Leibel. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 May; 18(9):1936-41. doi: 10.1200/jco.2000.18.9.1936. [PMID: 10784635]
  • K Kubota, T Tamura, M Fukuoka, K Furuse, H Ikegami, Y Ariyoshi, Y Kurita, N Saijo. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Apr; 11(4):445-50. doi: 10.1023/a:1008328207137. [PMID: 10847464]
  • N Takigawa, Y Segawa, H Ueoka, K Kiura, M Tabata, T Shibayama, I Takata, H Miyamoto, K Eguchi, M Harada. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 2000; 46(4):272-8. doi: 10.1007/s002800000153. [PMID: 11052624]
  • T Beinert, D Binder, C Oehm, S Ziemer, F Priem, M Schweigert, M Stuschke, M Fleischhacker, G Siebert, H G Mergenthaler, T G Werner, O Sezer, K Possinger. Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?. European journal of medical research. 1999 Aug; 4(8):328-34. doi: NULL. [PMID: 10471544]
  • H O Klein, G Demir. 'Multi-enzyme-targeted' immunochemotherapy: a salvage therapy protocol. Anticancer research. 1999 Jul; 19(4C):3451-8. doi: NULL. [PMID: 10629634]
  • Y Tada, T Yagi, F Yamagishi, F Mizutani, Y Sasaki, S Sakao, Y Takiguchi, S Nakamura, A Mikata. [A case of thymic carcinoma producing granulocyte colony-stimulating factor]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society. 1998 Dec; 36(12):1043-7. doi: NULL. [PMID: 10064959]
  • K Warzocha, P Ribeiro, J Bienvenu, P Roy, C Charlot, D Rigal, B Coiffier, G Salles. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998 May; 91(10):3574-81. doi: NULL. [PMID: 9572991]
  • N Morikawa, T Mori, M Takeyama, S Hori. Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. Biological & pharmaceutical bulletin. 1998 Mar; 21(3):297-9. doi: 10.1248/bpb.21.297. [PMID: 9556164]
  • N Morikawa, T Mori, T Abe, M Ghoda, M Takeyama, S Hori. Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid. The Annals of pharmacotherapy. 1997 Oct; 31(10):1153-6. doi: 10.1177/106002809703101007. [PMID: 9337440]
  • Y Akiyama, H Kondo, R Shirono, Y Fujii. [A case of lung adenocarcinoma associated with remarkably high levels of CA 19-9 and lymphangitis carcinomatosa]. Gan to kagaku ryoho. Cancer & chemotherapy. 1997 Jan; 24(1):93-6. doi: NULL. [PMID: 9020951]
  • N Tanigawa, A Kitaoka, M Yamakawa, K Tanisaka, H Kobayashi. In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis. Anticancer research. 1996 Jul; 16(4A):1925-30. doi: NULL. [PMID: 8712722]
  • M Kawasaki, Y Nakanishi, J Yatsunami, K Takayama, S Ochiai, P Xinhai, K Kuwano, N Hara. P53 immunostaining predicts chemosensitivity in non-small cell lung cancer: A preliminary report. The cancer journal from Scientific American. 1996 Jul; 2(4):217-20. doi: NULL. [PMID: 9166535]
  • S Matano, S Nakamura, K Kobayashi, T Misaki, T Matsuda, T Sugimoto. Decreased lymphocytic proliferation by mitogens in patients with transitional cell carcinoma of the renal pelvis subsequent to non-Hodgkin's lymphoma. American journal of hematology. 1996 Apr; 51(4):330-2. doi: 10.1002/1096-8652(199604)51:4<330::aid-ajh2830510406>3.0.co;2-7. [PMID: 8602639]
  • J H Li. [A study on treatment of lung cancer by combined therapy of traditional Chinese medicine and chemotherapy]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 1996 Mar; 16(3):136-8. doi: ". [PMID: 9208532]
  • M Masutani, H Akusawa, A Kadota, Y Ohchi, N Takahashi, S Tanigawa, Y Koya, T Horie. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology (Carlton, Vic.). 1996 Mar; 1(1):49-54. doi: 10.1111/j.1440-1843.1996.tb00010.x. [PMID: 9432405]
  • V Besnard, S Euvrard, J Kanitakis, F Mion, O Boillot, C Françès, M Faure, A Claudy. Kaposi's sarcoma after liver transplantation. Dermatology (Basel, Switzerland). 1996; 193(2):100-4. doi: 10.1159/000246221. [PMID: 8884143]
  • Y Takano, K Oida, Y Kohri, Y Taguchi, K Tomii, Y Matsumura, M Mino, I Gohma, T Inoue, Y Kobashi. [A case of lung cancer with choroidal metastasis]. Nihon Kyobu Shikkan Gakkai zasshi. 1995 Jun; 33(6):674-7. doi: NULL. [PMID: 7666626]
  • Y Myoken, T Sugata, T Kyo, M Fujihara. Oral Fusarium infection in a granulocytopenic patient with acute myelogenous leukemia: a case report. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 1995 May; 24(5):237-40. doi: 10.1111/j.1600-0714.1995.tb01174.x. [PMID: 7616464]
  • N Yamamoto, T Tamura, M Maeda, M Ando, T Shinkai, K Eguchi, Y Ohe, F Oshita, J Shiraishi, N Katsumata. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer chemotherapy and pharmacology. 1995; 36(2):102-6. doi: 10.1007/bf00689192. [PMID: 7767944]
  • L Brunetti, P Preziosi, E Ragazzoni, M Vacca. Effects of vindesine on hypothalamic-pituitary-adrenal axis. Toxicology letters. 1995 Jan; 75(1-3):69-73. doi: 10.1016/0378-4274(94)03162-z. [PMID: 7863539]
  • S Culine, M Bekradda, M J Terrier-Lacombe, J P Droz. Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy?. European urology. 1995; 27(2):138-41. doi: 10.1159/000475145. [PMID: 7744156]
  • M Delain, C Linassier, C Petitdidier, P Goupille, F Luthier, M Combe, M Reisenleiter, L Benboubker, J P Lamagnère, P Colombat. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Dec; 12(12):2706-13. doi: 10.1200/jco.1994.12.12.2706. [PMID: 7989948]
  • P Morel, B Dupriez, R Herbrecht, Y Bastion, H Tilly, A Delannoy, C Haioun, C Nouvel, K Bouabdallah, E Baumelou. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte. British journal of cancer. 1994 Jul; 70(1):154-9. doi: 10.1038/bjc.1994.267. [PMID: 7517172]
  • Y Masaki, S Shimizu, S Takeshita, M Fukutoku, R Yoshioka, T Arai, Y Hirose, S Sugai, S Konda, T Takiguti. [Successful VEP-IFN-alpha therapy in a case of non-secretory plasma cell leukemia (BJ-kappa type)]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 1994 Jun; 35(6):562-8. doi: NULL. [PMID: 8078191]
  • T Shinkai, H Arioka, H Kunikane, K Eguchi, Y Sasaki, T Tamura, Y Ohe, F Oshita, M Nishio, A Karato. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer research. 1994 May; 54(10):2636-42. doi: NULL. [PMID: 8168091]
  • C Battista, N Panza, B Chiurazzi, G Iodice, G Esposito, E Cocorocchio, N Bevilacqua, G Pacilio. Intermediate and high grade malignant non-Hodgkin's lymphomas: preliminary results using a new combination regimen (EVE-COPEM). Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 1993; 47(4):145-54. doi: 10.1016/0753-3322(93)90005-6. [PMID: 8018826]
  • T Miya, Y Sasaki, A Karato, N Saijo. Pharmacokinetic study of mitomycin C with emphasis on the influence of aging. Japanese journal of cancer research : Gann. 1992 Dec; 83(12):1382-5. doi: 10.1111/j.1349-7006.1992.tb02773.x. [PMID: 1336497]
  • P Havránek, A Rubenson, D Güth, B Frenckner, L Olsen, S A Kornfält, G Hansson. Sacrococcygeal teratoma in Sweden: a 10-year national retrospective study. Journal of pediatric surgery. 1992 Nov; 27(11):1447-50. doi: 10.1016/0022-3468(92)90197-f. [PMID: 1282543]
  • H Kikuchi, R Kanamaru. [Chemotherapy-associated hemolytic uremic syndrome--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy. 1992 Sep; 19(11):1927-9. doi: NULL. [PMID: 1519930]
  • K Mori, Y Saito, K Tominaga. Phase II study of cisplatin continuous infusion plus vindesine in the treatment of non-small-cell lung cancer. American journal of clinical oncology. 1992 Aug; 15(4):344-7. doi: 10.1097/00000421-199208000-00015. [PMID: 1325109]
  • K Furuse, M Fukuoka, H Asamoto, H Niitani, I Kimura, A Sakuma, Y Yamaguchi. [A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC)]. Gan to kagaku ryoho. Cancer & chemotherapy. 1992 Jul; 19(7):1019-26. doi: . [PMID: 1320846]
  • Y K Lee, D M Shin. Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer. The Korean journal of internal medicine. 1992 Jul; 7(2):118-21. doi: 10.3904/kjim.1992.7.2.118. [PMID: 1339077]
  • K Miyamoto, S Wakusawa, S Nakamura, K Tajima, H Hidaka. Multidrug resistance in Yoshida rat ascites hepatoma cell lines. Anticancer research. 1992 May; 12(3):649-53. doi: . [PMID: 1622121]
  • F Kimura, Y Takemura, T Ohtsuki, H Mizukami, S Takagi, K Yamamoto, N Nagata, K Motoyoshi. Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy. International journal of hematology. 1992 Apr; 55(2):147-55. doi: NULL. [PMID: 1511164]
  • S Hayashi, H Ogino, K Ogata, K Yagawa. Hypercoagulopathy induced by chemotherapy in a patient with lung cancer. A possible role for a factor with thrombosis-inducing activity (TIA). Chest. 1992 Jan; 101(1):277-8. doi: 10.1378/chest.101.1.277. [PMID: 1729088]
  • Y Saito, K Mori, K Tominaga, K Yokoi, N Miyazawa. Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 1992; 31(2):81-4. doi: 10.1007/bf00685091. [PMID: 1280537]
  • T Shinkai, K Eguchi, Y Sasaki, T Tamura, Y Ohe, A Kojima, F Oshita, T Miya, H Okamoto, K Iemura. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer chemotherapy and pharmacology. 1992; 30(1):1-6. doi: 10.1007/bf00686477. [PMID: 1316809]
  • K Kaito, M Kobayashi, T Katayama, S Ochiai, M Yoshida, H Masuoka, T Shimada, K Nishiwaki, A Saito, R Watanabe. [Pharmacokinetics of BHAC, VP-16 and Ara-C derived from BHAC in a hemodialysed patient with AMMoL]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 1991 Dec; 32(12):1558-63. doi: NULL. [PMID: 1779456]
  • A Fujita, Y Inoue, H Sasaki, S Nakajima, K Sekine, R Honda, M Asakawa, A Suzuki. [Cisplatin, ifosfamide and vindesine in the chemotherapy of squamous cell carcinoma of the lung]. Gan to kagaku ryoho. Cancer & chemotherapy. 1991 Oct; 18(13):2283-7. doi: NULL. [PMID: 1929449]
  • R M Bremnes, E Smeland, L Slørdal, E Wist, J Aarbakke. The effect of vindesine on methotrexate hydroxylation in the rat. Biochemical pharmacology. 1991 Sep; 42(8):1561-8. doi: 10.1016/0006-2952(91)90425-5. [PMID: 1930283]
  • M Kawahara, K Furuse, N Kodama, M Yamamoto, K Kubota, M Takada, S Negoro, Y Kusunoki, K Matui, N Takifuji. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer. 1991 Aug; 68(4):714-9. doi: 10.1002/1097-0142(19910815)68:4<714::aid-cncr2820680408>3.0.co;2-j. [PMID: 1649683]
  • T Fukabori, T Nakamura, T Kida, Y Fujita, T Goto, N Hiramori, T Fujii, Y Iwasaki, M Nakagawa. [Syndrome of inappropriate antidiuretic hormone secretion following cisplatinum and vindesine administration in a patient with squamous cell carcinoma of the lung]. Gan to kagaku ryoho. Cancer & chemotherapy. 1991 Jun; 18(7):1213-6. doi: NULL. [PMID: 2053780]
  • B Coiffier, C Gisselbrecht, J M Vose, H Tilly, R Herbrecht, A Bosly, J O Armitage. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Feb; 9(2):211-9. doi: 10.1200/jco.1991.9.2.211. [PMID: 1703226]
  • R Kobayashi, H Naito, T Shikano, Y Ishikawa, T Matsumoto, T Tonooka. [Nonoliguric acute renal failure complicated with tumor lysis syndrome in chronic myelocytic leukemia in lymphoid crisis]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 1991 Jan; 32(1):43-6. doi: NULL. [PMID: 2020116]
  • T Shinkai, K Eguchi, Y Sasaki, T Tamura, Y Ohe, A Kojima, F Oshita, N Saijo. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 1991; 27(5):571-5. doi: 10.1016/0277-5379(91)90220-8. [PMID: 1647183]
  • C J Twelves, J Goldman, C M Ash, R L Souhami, P G Harper, S G Spiro, D Geddes, J S Tobias. Sequential chemotherapy in good-prognosis patients with small-cell lung cancer. Cancer chemotherapy and pharmacology. 1991; 28(2):139-41. doi: 10.1007/bf00689704. [PMID: 1647892]
  • T Nagai, R Koyama, Y Sasagawa, S Matsumoto, Y Niitsu, S Takayama, T Murakami, A Matsuura. Diffuse infiltrating T-cell lymphoma of the colon associated with polyclonal hypergammaglobulinemia and hepatocellular carcinoma: report of a case. Japanese journal of medicine. 1991 Jan; 30(1):57-63. doi: 10.2169/internalmedicine1962.30.57. [PMID: 1650855]
  • J P Iredale, L M Hooi, K M Kerr, M F Sudlow, C G Wathen. Vindesine and etoposide chemotherapy in the management of patients with small cell lung cancer and poor prognosis. Respiration; international review of thoracic diseases. 1991; 58(2):77-80. doi: 10.1159/000195901. [PMID: 1650490]
  • H J König, W Gutmann, J Weissmüller. Ifosfamide, vindesine and recombinant alpha-interferon combination chemotherapy for metastatic renal cell carcinoma. Journal of cancer research and clinical oncology. 1991; 117 Suppl 4(?):S221-3. doi: 10.1007/bf01613231. [PMID: 1795011]
  • S Teramoto, T Nagase, Y Fukuchi, K Ishida, M Yamaoka, T Matsuse, C Jo, H Orimo. [Cisplatin and vinca alkaloid combination chemotherapy of advanced non-small-cell lung cancer in the aged]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics. 1990 Nov; 27(6):680-6. doi: 10.3143/geriatrics.27.680. [PMID: 1964186]
  • D J Straus, J J Gaynor, J Myers, D P Merke, J Caravelli, D Chapman, J Yahalom, B D Clarkson. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990 Jul; 8(7):1173-86. doi: 10.1200/jco.1990.8.7.1173. [PMID: 1694235]
  • H Scherübl, F Raue, R Ziegler. [Combination therapy with adriamycin, cisplatin and vindesine in C cell carcinoma of the thyroid]. Onkologie. 1990 Jun; 13(3):198-202. doi: 10.1159/000216758. [PMID: 2204006]
  • B Coiffier, S Demolombe, I Tabah. [Vindesine-interferon alpha-2b combination in the treatment of metastases of cancer of the kidney]. Presse medicale (Paris, France : 1983). 1990 May; 19(21):1009. doi: NULL. [PMID: 2141143]
  • M Fujii, Y Segawa, S Matsutomo, K Genba. [Phase II study of ifosfamide and vindesine combination of non-small cell lung cancer in elderly patients and patients with reduced renal function]. Gan to kagaku ryoho. Cancer & chemotherapy. 1990 May; 17(5):1021-5. doi: NULL. [PMID: 2159266]
  • L J Müller, C M Moorer-van Delft, R Zijl, E W Roubos. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents. Cancer research. 1990 Mar; 50(6):1924-8. doi: ". [PMID: 2407348]
  • N Takifuji, M Fukuoka, S Negoro, M Takada, Y Kusunoki, K Matsui, N Masuda, S Ryu, N Sakai, K Kubota. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy. 1990 Mar; 17(3 Pt 2):429-34. doi: NULL. [PMID: 2157364]
  • Y Saito, K Mori, K Tominaga, K Yokoi, N Miyazawa. Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 1990; 26(6):389-92. doi: 10.1007/bf02994086. [PMID: 2171793]
  • R Rahmani, X J Zhou, M Placidi, M Martin, J P Cano. In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide). European journal of drug metabolism and pharmacokinetics. 1990 Jan; 15(1):49-55. doi: 10.1007/bf03190127. [PMID: 2384117]
  • R Honda, A Fujita, Y Inoue, M Asakawa, A Suzuki. Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study. Cancer chemotherapy and pharmacology. 1990; 26(5):373-6. doi: 10.1007/bf02897297. [PMID: 2170045]
  • H Itoh, A Watanabe, T Ooka, I Shima, M Hayashi. [A case of breast cancer with multiple metastases to the lung and bone responding well to cisplatin and vindesine]. Gan to kagaku ryoho. Cancer & chemotherapy. 1989 Nov; 16(11):3631-4. doi: NULL. [PMID: 2817911]
  • H Lupera, C Theodore, M Ghosn, B H Court, P Wibault, J P Droz. Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer. Urology. 1989 Nov; 34(5):281-3. doi: 10.1016/0090-4295(89)90326-9. [PMID: 2815451]
  • H Ayabe, T Uchikawa, K Kimino, Y Tagawa, K Kawahara, M Tomita. [Pharmacokinetics of cisplatin and vindesine in a patient with chronic renal failure undergoing hemodialysis]. Gan to kagaku ryoho. Cancer & chemotherapy. 1989 Sep; 16(9):3283-5. doi: NULL. [PMID: 2782920]
  • T Nagase, Y Fukuchi, T Matsuse, K Marumo, M Yamaoka, T Suruda, S Homma, M Yoshikawa, H Orimo. [Cisplatin combination chemotherapy in advanced lung cancer in the aged]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics. 1989 Jul; 26(4):329-33. doi: 10.3143/geriatrics.26.329. [PMID: 2607673]
  • E Aboud-Pirak, B Lesur, K S Rao, R Baurain, A Trouet, Y J Schneider. Cytotoxic activity of daunorubicin or vindesin conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells. Biochemical pharmacology. 1989 Feb; 38(4):641-8. doi: 10.1016/0006-2952(89)90210-4. [PMID: 2917019]
  • M Naito, K Yusa, T Tsuruo. Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein. Biochemical and biophysical research communications. 1989 Feb; 158(3):1066-71. doi: 10.1016/0006-291x(89)92830-1. [PMID: 2563940]
  • A Hirosawa, H Niitani, K Hayashibara, E Tsuboi. Effects of sodium thiosulfate in combination therapy of cis-dichlorodiammineplatinum and vindesine. Cancer chemotherapy and pharmacology. 1989; 23(4):255-8. doi: 10.1007/bf00451652. [PMID: 2538252]
  • C H Ford, V J Richardson, G Tsaltas. Comparison of tetrazolium colorimetric and [3H]-uridine assays for in vitro chemosensitivity testing. Cancer chemotherapy and pharmacology. 1989; 24(5):295-301. doi: 10.1007/bf00304761. [PMID: 2788039]